Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Reprod Sci. 2022 Mar;29(3):823-835. doi: 10.1007/s43032-021-00769-y. Epub 2021 Oct 18.
The objective is to evaluate the effects of vitamin D3 (VD3) on sperm parameters and seminal and serum oxidative stress (OS) biomarkers in asthenozoospermia infertile men. This randomized, triple-masking, placebo-controlled clinical trial conducted on 86 asthenozoospermia infertile men with serum 25 hydroxy vitamin D3 (25-OH-D3) < 30 ng/ml in the infertility clinic of Ahvaz Jahad Daneshgahi, Iran. Patients were randomly allocated to groups A and B, who received daily 4000 IU vitamin D3 (VD3) and matching placebo respectively for 3 months. Demographic data, dietary intake, physical activity, sun exposure, anthropometric indices, serum and seminal levels of MDA (Malondialdehyde), 8-hydroxy-2- Dioxy Guanosine (8-OHDG), total antioxidant capacity (TAC) and calcium, sperm DNA fragmentation index (DFI), serum 25-OH-D3, parathyroid hormone (PTH), phosphorus, and sperm parameters were assessed. VD3 supplementation had no significant effects on body weight, body mass index (BMI), waist circumference (WC), body fat (BF), 8-OHDG, DFI, semen volume, sperm count, and normal sperm morphology, but increased post-intervention mean and mean change of serum 25-OH-D3 (P < 0.001, P < 0.001), PTH (P < 0.001, P < 0.001) and phosphorus (P = 0.009, P = 0.049) and seminal calcium (P = 0.035, P = 0.038) and serum calcium (P = 0.008, P = 0.009), seminal TAC (P < 0.001, P < 0.001), and serum TAC (P = 0.007, P = 005), total sperm motility (P < 0.001, P < 0.001) and progressive sperm motility (P < 0.001, P < 0.001) and decreased seminal MDA (P = 0.017, P = 0.004) and serum MDA (P = 006, P = 0.005) significantly compared to the baseline and placebo group respectively. VD3 supplementation may modulate OS and affect sperm motility in men with asthenozoospermia and serum 25-OH-D3 < 30 ng/ml. Iran Clinical Trials Registry, ID: IRCT20151128025274N4, registered on 28 March 2018, URL of trial registry record: https://www.irct.ir/trial/29983.
评估维生素 D3（VD3）对弱精子症不育男性精子参数以及精液和血清氧化应激（OS）生物标志物的影响。本随机、三盲、安慰剂对照临床试验在伊朗阿瓦兹 Jahad Daneshgahi 不孕不育诊所进行，纳入 86 例血清 25 羟维生素 D3（25-OH-D3）<30ng/ml 的弱精子症不育男性。患者被随机分为 A 组和 B 组，分别接受每日 4000IU 维生素 D3（VD3）和匹配的安慰剂治疗，持续 3 个月。评估了人口统计学数据、饮食摄入、体力活动、阳光照射、人体测量指数、血清和精液中丙二醛（MDA）、8-羟基-2-二氧鸟苷（8-OHDG）、总抗氧化能力（TAC）和钙、精子 DNA 碎片化指数（DFI）、血清 25-OH-D3、甲状旁腺激素（PTH）、磷和精子参数。VD3 补充剂对体重、体重指数（BMI）、腰围（WC）、体脂（BF）、8-OHDG、DFI、精液量、精子计数和正常精子形态没有显著影响，但增加了干预后血清 25-OH-D3 的平均值和平均值变化（P<0.001，P<0.001）、PTH（P<0.001，P<0.001）和磷（P=0.009，P=0.049）以及精液钙（P=0.035，P=0.038）和血清钙（P=0.008，P=0.009）、精液 TAC（P<0.001，P<0.001）和血清 TAC（P=0.007，P=0.005）、总精子活力（P<0.001，P<0.001）和前向精子活力（P<0.001，P<0.001）以及精液 MDA（P=0.017，P=0.004）和血清 MDA（P=0.006，P=0.005）与基线和安慰剂组相比均显著降低。VD3 补充剂可能调节 OS，并影响血清 25-OH-D3<30ng/ml 的弱精子症男性的精子活力。伊朗临床试验注册中心，注册号：IRCT20151128025274N4，于 2018 年 3 月 28 日注册，临床试验注册网址：https://www.irct.ir/trial/29983。
